A microdose of psilocybin is roughly 0.1 to 0.5 grams of dried psilocybin mushrooms, taken on a repeating schedule rather than all at once for a psychedelic experience. That translates to about one-fifth to one-twentieth of what someone would take for a full psychedelic trip. The goal is a dose low enough that you don’t feel any obvious altered state of consciousness, no visual distortions, no “trip,” but potentially enough to shift mood, focus, or creative thinking over time.
How Much Psilocybin Is in a Microdose
The most commonly cited range is 0.1 to 0.5 grams of dried Psilocybe cubensis mushrooms, with 0.3 grams being a typical starting point. Harvard Health describes a medium-strength psychedelic dose as 2 to 3 grams of dried mushrooms, so a microdose sits at roughly 10 to 15 percent of that.
In terms of actual psilocybin content, a double-blind study published in Translational Psychiatry measured the alkaloid concentrations in cubensis samples and found about 0.64 milligrams of psilocybin per gram of dried material. That puts a 0.3-gram microdose at roughly 0.2 milligrams of pure psilocybin. Mushrooms also contain psilocin, a closely related compound that’s actually the active form in your body, along with smaller amounts of baeocystin and norbaeocystin. The combined effect of all these alkaloids is part of why dried mushroom doses don’t map neatly onto a single milligram number.
Potency varies significantly between mushroom species, growing conditions, and even different parts of the same mushroom. This inconsistency is one of the practical challenges of microdosing: two capsules prepared from different batches might contain meaningfully different amounts of active compounds.
How It Works in the Brain
Psilocybin converts to psilocin in your body, and psilocin activates serotonin receptors, particularly one called 5-HT2A. At full psychedelic doses, intense activation of this receptor triggers hallucinations and altered perception. Research suggests that hallucinogenic effects require high activation of multiple signaling pathways at this receptor, with studies estimating that 50 to 70 percent of these receptors need to be occupied for an intense psychological experience.
At microdose levels, far fewer receptors are activated. Preclinical research on very low doses of related psychedelics has shown antidepressant-like effects in animals without triggering any hallucination-related brain activity. This suggests the mood-related benefits and the hallucinogenic effects may operate through partially separate mechanisms, meaning a sub-perceptual dose could theoretically influence mood without producing a “high.”
Common Dosing Schedules
Most people who microdose follow a structured protocol with built-in off days, rather than taking a dose every day. The two most widely discussed schedules are the Fadiman protocol and the Stamets protocol.
The Fadiman protocol, named after psychedelic researcher James Fadiman, involves taking a microdose every fourth day: one day on, three days off. This cycle typically runs for four to eight weeks, followed by a reset period of two to four weeks before starting again. The off days are considered important both for avoiding tolerance buildup and for observing how you feel without the dose as a baseline comparison.
The Stamets protocol, proposed by mycologist Paul Stamets, follows a different rhythm: four days on, three days off. Stamets also advocates combining the psilocybin microdose with lion’s mane mushroom and niacin (vitamin B3). The idea behind adding lion’s mane is that compounds in its mycelium may support nerve growth factors. Niacin, specifically the flushing form (nicotinic acid), was originally included partly as an active placebo in research settings. Because niacin causes a warm, flushing sensation within 15 to 20 minutes, roughly the same onset window as psilocybin, it helps blind study participants to whether they received a real dose or a placebo.
Many people ultimately customize their schedule based on personal response. Some dose only when they feel they need it rather than following a fixed calendar.
What the Clinical Evidence Actually Shows
This is where the story gets complicated. Survey-based and observational studies have reported a wide range of benefits from microdosing, including improvements in attention, mood, creativity, social cognition, and general well-being. These self-reports are what drive most of the popular enthusiasm around the practice.
When researchers test these claims in controlled settings, the results are far less impressive. Two double-blind, placebo-controlled trials on psilocybin microdosing found no significant effects on attention, mood, cognitive control, or self-reported well-being compared to placebo. Some initial effects appeared in areas like social cognition and cognitive flexibility, but these vanished after proper statistical correction. The researchers concluded that their findings “do not support the idea that microdosing psilocybin reliably enhances cognitive or emotional functioning beyond placebo.”
This doesn’t necessarily mean microdosing does nothing. It may mean the effects are smaller than people believe, highly individual, or driven substantially by expectation. The placebo effect is powerful, especially when someone has invested time, money, and hope into a practice. It’s also possible that current studies haven’t captured the right outcomes, used the right doses, or run long enough. But as of now, the gap between what people report and what controlled trials confirm is wide.
Potential Risks and Safety Concerns
Because microdoses are small, people often assume they’re harmless. The acute risks are indeed low compared to a full psychedelic dose, but there are concerns worth knowing about, especially with long-term use.
The most discussed safety question involves heart health. Both psilocybin and LSD share structural similarities with drugs known to cause heart valve damage and cardiac fibrosis when taken regularly, including medications like fenfluramine and pergolide. These drugs cause problems through chronic activation of the 5-HT2B serotonin receptor in heart tissue. Since microdosing involves repeated dosing over weeks, months, or even years, some researchers have flagged this as a potential concern that needs formal study. No cases of microdosing-related heart valve damage have been documented, but no long-term cardiac safety studies have been conducted either.
Drug interactions are another consideration. Psilocybin and common antidepressants (SSRIs, SNRIs) both act on the serotonin system. Clinical trials typically require participants to stop serotonin-targeting antidepressants at least two weeks before receiving psilocybin. Combining them could blunt the effects of the psilocybin, alter the effects of the antidepressant, or in theory contribute to excess serotonin activity.
Certain psychiatric conditions are generally considered contraindications. People with bipolar disorder, schizophrenia, psychotic disorders, or a family history of these conditions face elevated risk from any psychedelic use, even at low doses. Psilocybin’s action on serotonin receptors can potentially trigger manic or psychotic episodes in vulnerable individuals.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law, making it illegal to possess, grow, or distribute in most of the country. However, a patchwork of state and local laws has created exceptions.
Oregon became the first state to legalize psilocybin-assisted therapy in 2020, with licensed service centers now operating. Colorado followed in 2022 with Proposition 122, legalizing regulated therapeutic use. New Mexico signed its Medical Psilocybin Act into law in April 2025, with a system expected to launch in late 2026. New Jersey established a pilot program at three hospitals in early 2026. Washington state has a psilocybin therapy pilot program specifically for veterans and first responders through the University of Washington.
At the city level, Denver was the first U.S. city to deprioritize enforcement for psilocybin possession in 2019. Several California cities, including Oakland, Santa Cruz, San Francisco, Berkeley, Arcata, and Eureka, have passed resolutions making personal use the lowest law enforcement priority. Ann Arbor, Detroit, and Hazel Park in Michigan have similar measures, as does Minneapolis. These local policies don’t make psilocybin legal, but they direct police to treat possession as their lowest priority.
None of these legal frameworks specifically authorize unsupervised microdosing at home. The state-level programs are designed around supervised therapeutic sessions with trained facilitators, typically using full doses rather than microdoses.